



INTERNATIONAL ACADEMY OF CARDIOLOGY  
**18th WORLD CONGRESS ON HEART DISEASE**  
ANNUAL SCIENTIFIC SESSIONS 2013  
VANCOUVER, BC, CANADA, JULY 26-29, 2013

**PRELIMINARY LIST OF SCIENTIFIC PRESENTATIONS**

**MOLECULAR SURVIVAL AND REGENERATION IN CARDIAC DISEASE**

**Pericytes for Cardiovascular Regeneration**

*Paolo Madeddu*, University of Bristol, Bristol, UK

**Enhancing Stem Cell Engraftment in the Heart Using Single Cell Microencapsulation**

*Dara L. Kraitchman*, Johns Hopkins University, Baltimore, MD, USA

**Cardioprotection by Autophagy Mediated Via Endoplasmic Reticulum Stress**

*Dipak K. Das*, University of Connecticut School of Medicine, Farmington, CT, USA

**Cardiac Tissue Hypothyroidism- A Major Player in Diabetic Cardiomyopathy**

*A. Martin Gerdes*, New York Institute of Technology, Old Westbury, NY, USA

**Thioredoxin-1 Gene Therapy for Cardiovascular Disease**

*Nilanjana Maulik*, University of Connecticut School of Medicine, Farmington, CT, USA

**DNA Topoisomerase II Inhibitors Induce Macrophage ABCA1 Expression and Cholesterol Efflux-An LXR-Dependent Mechanism**

*Jihong Han*, Nankai University, China

**Failure to Overexpress Urocortin Following Cardioplegic Arrest makes the Heart of Diabetic Patients Undergoing On-pump Coronary Artery Bypass Grafting More Susceptible to Apoptosis and Cardiac Dysfunction Worsening Postsurgical Outcomes**

*Tiziano M. Scarabelli*, Wayne State University School of Medicine, Detroit, MI, USA

**PI3K Inhibitors as Novel Cancer Therapies: Implications for Cardiovascular Medicine**

*Gavin Y. Oudit*, University of Alberta, Edmonton, AB, Canada

**Protein Transduction Domains; Targeted vs. Non-Targeted Tissue Delivery**

*Maliha Zahid*, University of Pittsburgh, Pittsburgh, PA, USA

**Mechanisms of Cardiac Regeneration in Doxorubicin Induced Cardiomyopathy Following Stem Cells Transplantation**

*Dinender K. Singla*, University of Central Florida, Orlando, FL, USA

**VASCULAR BIOLOGY, IMMUNE MEDIATED SURVIVAL AND OXIDATIVE STRESS**

**mTOR Signaling in Vascular and Immune Mediated Disease**

*Kenneth Maiese*, Mitsubishi Tanabe Pharma, Jersey City, NJ, USA

**Coronary Vasomotor Regulation by Endothelin-1 and Oxidative Stress**

*Lih Kuo*, Texas A&M Health Science Center, Temple, TX, USA

**The Role of IL-10 in Cell Survival and Mitigation of Heart Failure**

*Pawan K. Singal*, St. Boniface General Hospital Research Centre, Winnipeg, MN, Canada

**The Role of Nitric Oxide/Peroxynitrite Imbalance in the Ischemic Heart**

*Tadeusz Malinski*, Ohio University, Athens, OH, USA

**A Novel Role of Endothelial Dihydrofolate Reductase in Cardiovascular Pathophysiology**

*Hua Linda Cai*, UCLA David Geffen School of Medicine Los Angeles, CA, USA

**Hypercholesterolemia-Induced Oxidative Stress in the Heart**

*Kailash Prasad*, University of Saskatchewan, Saskatoon, SK, Canada

**Role of Cross-Talk between NADPH Oxidase and Mitochondria for Regulating VEGF Signaling and Angiogenesis**

*Masuko Ushio-Fukai*, University of Illinois at Chicago, Chicago, IL, USA

**Statin Effects beyond Lipid Lowering: Atorvastatin Inhibition of Myocardin Expression in Vascular Smooth Muscle**

*Xi-Long Zheng*, University of Calgary, Calgary, AB, Canada

**INFLAMMATION / INNATE AND ADOPTIVE IMMUNITY AND CARDIOVASCULAR DISEASES**

**Inflammation - The New Target for Prevention of Coronary Artery Disease**

*Robert Roberts*, University of Ottawa Heart Institute, Ottawa, ON, Canada

**Sepsis and the Cardiovascular System: Going to the Heart of the Matter**

*Marcos A. Rossi*, University of Sao Paulo, Brazil

**Neutrophils in Acute Coronary Artery Disease**

*Janos G. Filep*, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada

**Interaction of Gene and Salt Diets on Cardiac Angiotensin II, Aldosterone, and Cytokines in Hypertrophied Heart**

*Kailash N. Pandey*, Tulane University School of Medicine, New Orleans, LA, USA

**Microbiota, Systemic Inflammation and Cardiovascular Function**

*Mohamad Navab*, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

**Role of Copper Transporters in Vascular Remodeling and Inflammation**

*Tohru Fukai*, University of Illinois at Chicago, Chicago, IL, USA

**The Complex Cardiovascular Effects of Leptin**

*Matthew A. Allison*, University of California, San Diego, La Jolla, CA, USA

**Human Enterovirus Persistence: Potential for Exacerbation of Viral Inflammatory Heart Disease**

*Nora M. Chapman*, University of Nebraska Medical Center, Omaha, NE, USA

**The Cytokines and the Role of Immunomodulation in Heart Failure**

*Sergio Dalla-Volta*, Universita degli Studi di Padova, Padova, Italy

## **CARDIOVASCULAR IMAGING MODALITIES FOR EVALUATION OF CORONARY CIRCULATION, CARDIAC STRUCTURE AND FUNCTION**

### **Newer Aspects of Evaluating LV Function by Echocardiograph**

*Navin C. Nanda*, University of Alabama at Birmingham, Birmingham, AL, USA

### **Flurpiridaz F 18 PET Versus TC-99m SPECT For Myocardial Perfusion Imaging**

*D.S. Berman*, Cedars-Sinai Medical Center; Los Angeles, California, USA

### **Usefulness of Optical Coherence Tomography in Daily Clinical Practice**

*Takashi Akasaka*, Wakayama Medical University, Wakayama, Japan

### **Myocardial Strain for the Assessment of LV Function**

*Sherif F. Nagueh*, Methodist DeBakey Heart and Vascular Center, Houston, TX, USA

### **Screening for Asymptomatic Coronary Artery Disease: Seeking Value in a Multi-Modality World**

*J.J. Mahmarian*, Methodist DeBakey Heart & Vascular Center, The Methodist Hospital, Houston, TX, USA

### **Myocardial Viability and Outcomes in Ischemic Cardiomyopathy**

*Jamshid Shirani*, St. Luke's Hospital and Health Network, Bethlehem, PA, USA

### **Novel Uses of Cardiac MRI for Non-Ischemic Heart Disease**

*Robert W.W. Biederman*, Temple University School of Medicine, Carnegie Mellon University, Allegheny General Hospital, Pittsburgh, PA, USA

### **Prognostic Value of Stress Echocardiography in Patients with Coronary Artery Disease**

*Maria Prokudina*, Federal Center of Heart, Blood and Endocrinology, St. Petersburg, Russia

### **Non-invasive Cardiovascular Imaging for Evaluation of Coronary Artery Bypass Graft Disease**

*Abdou Elhendy*, Marshfield Clinic, Marshfield, WI, USA

### **Optical Coherence Tomography. What you need to know**

*Joel A. Garcia*, Denver Health Medical Center (DHMC) and University of Colorado Hospital at Denver, Denver, CO, USA

### **New Insights on Myocardial and Arterial Viscoelasticity and Stiffness Measured In Vivo by New Shear Wave Methods**

*Cristina Pislaru*, Mayo Clinic College of Medicine, Rochester, MN, USA

## **DISEASE MECHANISMS LEADING TO CARDIOMYOPATHY AND HEART FAILURE**

### **Advances in Pathophysiology and Management of Diastolic Heart Failure**

*Kanu Chatterjee*, University of Iowa, IA, USA

### **Reversal of Cardiac Remodeling in Heart Failure by $\alpha$ -Adrenoceptor Blockade**

*Naranjan S. Dhalla*, St. Boniface General Hospital Research Centre, Winnipeg, MN, Canada

### **Aging and Heart Failure. Update**

*Bodh I. Jugdutt*, University of Alberta and Hospitals, Edmonton, AB, Canada

### **Mitochondrial Fission and Fusion in Heart Failure**

*Anne A. Knowlton*, University of California, Davis, CA, USA

**Personalized Medicine in Dilated Cardiomyopathy**

*Luisa Mestroni*, University of Colorado Cardiovascular Institute, Aurora, CO, USA

**Genetic Epidemiology of Left Ventricular Hypertrophy**

*Jonathan N. Bella*, Bronx-Lebanon Hospital Center, Bronx, NY, USA

**Blunted Responses of Renal Sympathetic Nerve Activity to C-Type Natriuretic Peptide in the PVN of Rats with Heart Failure**

*Kaushik P. Patel*, University of Nebraska Medical Center, Omaha, NE, USA

**CPT1b Deficiency Is Bad For the Hypertrophied Heart**

*Qinglin Yang*, University of Alabama at Birmingham, Birmingham, AL, USA

**Deletion of the Translational Repressors Eukaryotic Translation Initiation Factor 4E Binding Proteins 1 And 2 Protects Against Pressure Overload Induced Heart Failure**

*Yingjie Chen*, University of Minnesota, MN, USA

**Residual Myocardial Injury and Attenuated Production of Vascular Endothelial Growth Factor (VEGF) in Patients with Recovered Peripartum Cardiomyopathy (PPCM)**

*Sorel Goland*, Kaplan Medical Center, Rehovot, Israel

**Cardiac Fibroblasts: Friend or Foe in Cardiac Remodeling?**

*Burns C. Blaxall*, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

**ADVANCES IN THE TREATMENT AND MANAGEMENT OF HEART FAILURE**

**Circulating microRNAs as Biomarkers in Heart Failure: Outcomes of the First Large Studies**

*Yigal Pinto*, Heart Centre at the University of Amsterdam, Amsterdam, The Netherlands

**New Therapies for Diastolic Heart Failure**

*Samuel C. Dudley*, University of Illinois at Chicago, Chicago, IL, USA

**Partial Adenosine A1-Receptor Agonists for the Treatment of Heart Failure**

*Hani N. Sabbah*, Henry Ford Heart & Vascular Institute, Detroit, MI, USA

**Enhancing Glucose Oxidation as an Approach to Treat Heart Failure**

*Gary Lopaschuk*, University of Alberta, Edmonton, AB, Canada

**The Management of Patients with Advanced Heart Failure**

*Maria Vittoria H. Pitzalis Zapler*, East Carolina University, Greenville, NC, USA

**Ultrafiltration in the Treatment of Volume Overload Due to Heart Failure**

*Uri Elkayam*, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA

**Role of Peritoneal Dialysis in Management of Heart Failure: an Update for 2013**

*Amir Kazory*, University of Florida, Gainesville, FL, USA

**Biomarker Solutions for Heart Failure and COPD Management**

*Bruce M. McManus*, St. Paul's Hospital, Vancouver, BC, Canada

**Benefit of Heart Rate Reduction in Ischemic Heart Disease and Heart Failure**

*Giuseppe M.C. Rosano*, IRCCS San Raffaele, Rome, Italy

**Predominant Differential Cause of Dyspnea in Atrial Fibrillation and Coincident COPD. Inflammation, Latent Ischemia and Myocardial Dysfunction, Thrombogenesis, Apoptosis and Cardiovascular Remodeling or Respiratory Impairment?**

**Nestor J. Angomachalelis**, Aristotle University, School of Medicine, Thessaloniki, Macedonia, Greece

**Efficacy and Safety of Ivabradin in Patients with Idiopathic Dilated Cardiomyopathy**

**Shorena Chumburidze**, Scientific Research Clinic of Therapy, Tbilisi, Rep. of Georgia

**SUDDEN CARDIAC DEATH / ADVANCES IN IMPLANTABLE RHYTHM DEVICE THERAPY**

**Impact of Denervated Myocardium on Improving Risk Stratification for Sudden Cardiac Death**

**Michael E. Cain**, University at Buffalo, Buffalo, NY USA

**Catheter Ablation in Patients with Electrical Storm - Benefit of a Clinical Network**

**Thomas Deneke**, University of Bochum, Bochum, Germany

**The Role of Electrophysiologic Testing on Outcome in Patients with ARVC**

**Firat Duru**, University Hospital of Zurich, Switzerland

**Robotics in the EP Laboratory: Promise, Reality and Future Directions**

**Eli Gang**, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

**Biventricular versus Right Ventricular Pacing in Patients with Left Ventricular Dysfunction and Atrioventricular Block: The Block HF Study**

**Anne B. Curtis**, University at Buffalo, Buffalo, NY, USA

**Limitations of Resynchronization Therapy in Patients with Narrow QRS: Insights from the EARTH Trial**

**Bernard Thibault**, Montreal Heart Institute, Montreal, Canada

**In the OR v. The EP Lab--Where Is the Best Location for Lead Extraction**

**Charles Henrikson**, Oregon Health & Science University, Portland, OR, USA

**Catecholaminergic Polymorphic Ventricular Tachycardia - The Clinician's Perspective**

**Martin J. LaPage**, University of Michigan, Ann Arbor, MI, USA

**Genetic Background, Clinical Characteristics, and Treatment of Early Repolarization Syndrome**

**Hiroshi Watanabe**, Niigata University Graduate School of Medical & Dental, Asahimachidori, Niigata, Japan

**The Evolution of the Pacing Site: Past, Present and Future**

**Yasushi Oginosawa**, University of Occupational and Environmental Health, Yahatanishi, Kitakyushu, Japan

**ARRHYTHMIA, ELECTROPHYSIOLOGY AND STROKE PREVENTION**

**The Work Up of Asymptomatic Wolff-Parkinson-White Syndrome**

**Christopher S. Snyder**, Rainbow Babies and Children's Hospital, Cleveland, OH, USA

**Atrial Fibrillation as a Genetic Disease**

**Michael H. Gollob**, University of Ottawa Heart Institute, Ottawa, Ontario, Canada

**Is there a Perfect Approach for Ablation Persistent Atrial Fibrillation?**

**Komandoor Srivathsan**, Mayo Clinic, Arizona, AZ, USA

**Thoracoscopic Biatrial Maze Procedure – A Novel Minimal-Invasive Remedy with Promising Midterm Results**

**Ali Khojnejhad**, Cedars-Sinai Medical Center, Los Angeles, CA, USA

**Left Atrial Appendage Closure**

**Stefan Bertog**, CVC Frankfurt/Minneapolis VA Medical Center, MN, USA

**New Anticoagulants in AF Therapy: What Benefits the Patient Most?**

**Alessandro Capucci**, Universita Politecnicadelle Marche, Ancona, Italy

**Anticoagulation in Patients with Systolic Heart Failure and Sinus Rhythm: When?**

**Ertan Yetkin**, Middle East Hospital, Mersin, Turkey

**Cryptogenic Stroke - Could Long Term Cardiac Monitoring Uncover the Cause**

**J. Rod Gimbel**, Knoxville, TN, USA

**My Patient Cannot Stand Up: What to do about Orthostatic Hypotension**

**Satish R. Raj**, Vanderbilt University, Nashville TN, USA

**THE KIDNEY, BLOOD PRESSURE AND HYPERTENSION MANAGEMENT**

**Optimal Blood Pressure Goals in Patients at High Risk for Cardiovascular Events**

**Wilbert S. Aronow**, New York Medical College, Valhalla, NY, USA

**Dual RAAS Blockade: Too much of a Good Thing?**

**Alexander H. Danser**, Erasmus Medical Center, Rotterdam, The Netherlands

**Novel Technologies to Manage Blood Pressure in Patients with Autonomic Dysfunction**

**Andre Diedrich**, Vanderbilt University School of Medicine, Nashville, TN, USA

**Natriuretic Peptide Receptor-C, Gi Proteins and Regulation of Blood Pressure**

**Madhu B. Anand-Srivastava**, University of Montreal, Montreal, QC, Canada

**Role of Ingestion-Time of Renin-Angiotensin Blockade for Reducing Blood Pressure and Cardiovascular Risk**

**Ramon C. Hermida**, Campus Universitario Vigo, Pontevedra, Spain

**Renal Denervation in Hypertension and More?**

**Felix Mahfoud**, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany

**Use of Ambulatory Blood Pressure Monitor (ABPM) for Guiding Cardiac Patients Management**

**Yzhar Charuzi**, UCLA School of Medicine, CA, USA

**Chronotherapy with Low-Dose Aspirin for Prevention of Complications in Pregnancy**

**Diana E. Ayala**, Campus Universitario, Vigo, Spain

## **CAN WE BUILD A BETTER MODEL: CVD RISK PREDICTION**

### **Coronary Artery Calcium Density and Cardiovascular Events**

**Michael H. Criqui**, University of California, San Diego, La Jolla, CA, USA

### **Carotid Ultrasound Evaluation of Subclinical Atherosclerosis in 2013: Progress and Pitfalls**

**Julius M. Gardin**, Hackensack University Medical Center, Hackensack, NJ, USA

### **Is Diabetes Really a Coronary Heart Disease Risk Equivalent?**

**Nathan D. Wong**, University of California, Irvine. CA, USA

### **Risk Factors for Cardiovascular Disease in Patients with Chronic Kidney Disease**

**Martin Alpert**, University of Missouri-Columbia, Columbia, MO, USA

### **The High Coronary Disease Risk of South Asian Americans**

**Arthur L. Klatsky**, Kaiser Permanente Medical Center, Oakland, CA, USA

### **Psychosocial Risks and Mental Stress Induced Myocardial Ischemia in Patients with Ischemic Heart Disease**

**Wei Jiang**, Duke University Medical Center, Durham, NC, USA

### **Bidirectional Risks of Cardiovascular Disease and Cognitive Impairment**

**Kannayiram Alagiakrishnan**, University of Alberta, Edmonton, Alberta, Canada

### **Are Gender Differences in Heart Disease more Significant than the Similarities?**

**Shaista Malik**, UC Irvine, CA, USA

### **Lipoprotein-associated Phospholipase A2 as a Novel Risk Marker for Cardiovascular Disease and a Potential Target for Therapy**

**Mohammad Madjid**, Texas Heart Institute, Houston, TX, USA

## **PREVENTION OF CARDIOVASCULAR DISEASE: ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR RISK**

### **Gender Differences in Cardiovascular Medicine**

**Vera Regitz-Zagrosek**, Center for Cardiovascular Research (CCR) Coordinator Berlin, German

### **The Association between Depression and Diabetes**

**Elizabeth Barrett-Connor**, UCSD Dept. of Family and Preventive Medicine, La Jolla, CA, USA

### **Aldosterone - A Bridge Between Cardiovascular and Mood Disorders?**

**Daniela Jezova**, Slovak Academy of Sciences, Bratislava, Slovak Republic

### **HDL and the Atherosclerosis - Myth or Reality**

**Robert S. Rosenson**, Mount Sinai Heart Mount Sinai School of Medicine, New York, NY, USA

### **Omega-3 Supplementation Improves Arterial Stiffness and Biomarkers of CV Risk in Latino and White Patients with Hypertension Served By a Safety-Net Healthcare System**

**Carlin S. Long**, University of Colorado Health Sciences Center and Denver Health Medical Center, Denver, CO, USA

**Impact of Renal Sympathetic Denervation in Patients with Drug Resistant Hypertension**

**Karlheinz Seidl**, Klinikum Ingolstadt GmbH, Ingolstadt, Germany

**How much of the CVD Risk is attributed to Diet?**

**Demosthenes B. Panagiotakos**, Harokopio University of Athens, Athens, Greece

**Beyond HDL Cholesterol: What Can We Learn from HDL Particle Number and Size?**

**Samia Mora**, Brigham and Women's Hospital, Boston, MA, USA

**Dysfunctional HDL - Novel Biomarker of Lipid Disorders?**

**Maciej Banach**, Medical University of Lodz, Poland

**Sex Matters: Differences in Associations between Risk Factors and Cardiovascular Disease**

**Rachel Huxley**, University of Minnesota School of Public Health, Minneapolis, MN, USA

**STABLE ISCHEMIC HEART DISEASE – THERAPEUTIC OPTIONS**

**Women and Heart Disease: A Fresh Perspective**

**Ezra A. Amsterdam**, University of California, Davis Medical Center, Sacramento, CA, USA

**Impact of Life Style Modifications, Antianginals, Antiplatelets and Lipid Modifying Drugs and of Coronary Artery Revascularization on Mortality and Morbidity in Patients with Ischemic Heart Disease: Truth and False Notions**

**Udho Thadani**, University of Oklahoma HSC and VA Medical Center, Oklahoma City, OK, USA

**Integrative Therapy in Cardiovascular Disease: Savior or Sham?**

**Saul Schaefer**, University of California, Davis, CA, USA

**Medical Risk Factor Control in Large Trials of Diabetic Patients Undergoing Coronary Revascularization**

**Michael E. Farkouh**, University of Toronto, Toronto, Ontario, Canada

**PTEN and Statins Induced New Onset Diabetes**

**Yochai Birnbaum**, Baylor College of Medicine, Houston, TX, USA

**Anti-Atherosclerotic Effects of Incretin Based Therapies**

**Ishwarlal Jialal**, UC Davis Medical Center, Sacramento, CA USA

**Advances in the Treatment of Coronary Artery Disease in the Elderly**

**Issam Mikati**, Northwestern Memorial Hospital, Chicago, IL, USA

**Is There a Role for Coronary Artery Calcium (CAC) Testing in Symptomatic Patients in the Era of Coronary CT Angiography?**

**Khurram Nasir**, Baptist Health South Florida, Johns Hopkins Ciccarone Center for Preventive Cardiology, Miami, FL, USA

**A New Strategy for Discontinuation of Dual Antiplatelet Therapy: The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)**

**Myeong-Ki Hong**, Severance Cardiovascular Center and Severance Biomedical Science Institute, Seoul, Korea



## **CURRENT CONCEPTS AND FUTURE DIRECTIONS IN ISCHEMIC HEART DISEASE AND ACUTE CORONARY SYNDROMES**

### **Why ACS Occurs and How We Can Prevent It**

*Yasunori Ueda*, Osaka Police Hospital, Tennoj-ku, Osaka, Japan

### **High Sensitivity Troponins: A Step Forward or an Unrequested Complication?**

*Luigi M. Biasucci*, Policlinico A. Gemelli, Catholic University of the Sacred Heart Largo, Rome, Italy

### **The Complicated STEMI: What to Do With Multivessel Disease**

*Gregory W. Barsness*, Mayo Clinic, Rochester, MN, USA

### **Emboic protection in STEMI**

*Edo Kaluski*, University Hospital, Newark, NJ, USA

### **Femoral or Radial Access for Primary PCI: A Dilemma of Choice**

*Asim N. Cheema*, St. Michael's Hospital, Toronto, ON, Canada

### **Trends in Management and Outcome of Hospitalized Patients with Acute Coronary Syndromes in the Last Decade: The ACS Israeli Survey (ACSIS) Experience**

*Shmuel Gottlieb*, Jerusalem, Israel

### **Recurrent Versus First, ST-Elevation versus Non-ST-Elevation Myocardial Infarction: Results from national Israel surveys ACSIS 2000-2010**

*Avraham Shotan*, Hillel Yaffe Medical Center, Hadera, Israel

### **Prevention of Reperfusion Injury in Patients with ST Elevation Myocardial Infarction: The cGMP Pathway**

*David Garcia-Dorado*, Vall d'Hebron University Hospital and Research Institute Universitat Autònoma de Barcelona, Barcelona, Spain

### **Protective Effect of Telmisartan against Endothelial Dysfunction after Coronary Drug-Eluting Stent Implantation in Hypertensive Patients**

*Mitsuyasu Terashima*, Toyohashi Heart Center, Toyohashi, Japan

### **New Insights into Spontaneous Coronary Artery Dissection**

*Rajiv Gulati*, Mayo Clinic, Rochester, MN, USA

## **PATHOGENESIS, DIAGNOSIS AND TREATMENT OF AORTIC ANEURYSMS AND PERIPHERAL ARTERY DISEASE**

### **Practical Genetics of Thoracic Aortic Aneurysm**

*J.A. Elefteriades*, Aortic Institute at Yale-New Haven, New Haven, CT, USA

### **Update on AHA Guidelines for Management of Thoracic Aortic Disease**

*Angela T. Yetman*, University of Utah, Salt Lake City, UT, USA

### **Lessons from Animal Models of Arterial Aneurysm**

*S. David Gertz*, The Hebrew University - Hadassah Medical School, Jerusalem, Israel

### **Polyvascular Disease: Diagnosis and Treatment**

*Takanobu Tomaru*, Toho University Sakura Hospital, Japan

**Ige Activities on CD4+ T Cells Are Equally Important To Those on Mast Cells in Experimental Abdominal Aortic Aneurysms**

*Guo-Ping Shi*, Brigham and Women's Hospital, Boston, MA, USA

**Drug Eluting Balloons and Stents for Endovascular Treatment of Peripheral Arterial Disease**

*Subhash Banerjee*, VA North Texas Healthcare System, Dallas, TX, USA

**The Multilayer Flow Modulator Stent (MFM) For the Treatment of Aortic Aneurysms**

*Michel Henry*, Nancy, France

**VALVULAR HEART DISEASE: MECHANISMS, IMAGING AND TREATMENT OPTIONS (I)**

**Anticoagulation and Heart Valve Disease: Is it Time to Reconsider Who and How?**

*Jeffrey S. Borer*, State University of New York Downstate Medical Center, New York, NY, USA

**New Insight into Treatment of Aortic Stenosis: Light at the End of the Tunnel**

*Donald D. Heistad*, University of Iowa College of Medicine, Iowa City, IA, USA

**Oxidative-Mechanical Signaling Activates Wnt3a-Lrp5 Mediated Aortic Valve Osteogenesis in Bicuspid Aortic Valve Disease**

*Nalini M. Rajamannan*, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

**Transapical Transcatheter Aortic Valve Replacement in the Presence of a Mitral Prosthesis**

*Jian Ye*, University of British Columbia, Vancouver, BC, Canada

**Evolving Treatment Strategies for Tricuspid Valve Disease**

*Hanumanth Reddy*, University of Arkansas for Medical Sciences, Little Rock, AR, USA

**TAVI: Wave of the Future or Time for a Deep Breath?**

*Harold L. Lazar*, Boston Medical Center, Boston, MA, USA

**Echocardiography for TAVR**

*Stamatios Lerakis*, Emory University Hospital, Atlanta, GA, USA

**Asymptomatic Severe Aortic Stenosis: Operate or Wait?**

*Hari P. Chaliki*, Mayo Clinic, Scottsdale, AZ, USA

**Early Surgery in Mitral Regurgitation: Is it a New Trend?**

*Yong-Jin Kim*, Seoul National University College of Medicine, Chongno-gu, Seoul, Korea

**Major Non-cardiac Surgery in Patients with Aortic Stenosis - Same as 20 years ago?**

*Sorin Pislaru*, Mayo Clinic College of Medicine, Rochester, MN, USA

**Surgical Timing for Infective Endocarditis**

*Duk-Hyun Kang*, University of Ulsan, Asan Medical Center, Seoul, Korea

**ADVANCES IN CARDIOVASCULAR SURGERY, HEART TRANSPLANTATION, CAROTID AND CORONARY REVASCULARIZATION**

**Changes in Heart Allocation for Transplantation in the US and Worldwide: Options for a Better Solution**

*Dan M. Meyer*, University of Texas Southwestern, Med Center at Dallas, Dallas, TX, USA

**Simultaneous Heart-Kidney Transplantation**

**Maryl R. Johnson**, University of Wisconsin-Madison, Madison, WI, USA

**Where is the Fine Balance between Immune suppression and Malignancy in Cardiac Transplantation?**

**Nandini Nair**, Texas A&M HSC College of Medicine, Temple, TX, USA

**Assist device in the Elderly**

**Roland Hetzer**, German Heart Institute, Berlin, Germany

**Update on the Use of Impella Assist Device for High Risk Patients Undergoing Percutaneous Coronary Interventions**

**Mohammad-Reza Movahed**, University of Arizona Sarver Heart Center, Tucson, AZ, USA

**New Strategies for Acute Stroke Intervention**

**Horst Sievert**, CardioVascular Center Frankfurt, Frankfurt, Germany

**Device Closure of ASD- Long-Term Follow Up with Special Reference to Complications**

**Masood Sadiq**, The Children's Hospital, Punjab Institute of Cardiology, Lahore, Pakistan

**Update on the Treatment of Left Main Disease**

**Barry F. Uretsky**, University of Arkansas for Medical Sciences, Little Rock, AR, USA

**California Revascularization: PCI and CABG outcomes in the Sunshine State**

**William Bommer**, University of California Davis, Medical Center, Davis, CA, USA

**Management Strategies of Combined Severe Symptomatic Carotid and Coronary Artery Disease**

**Mazen Abu-Fadel**, University of Oklahoma HScC, Oklahoma City, OK, USA